Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Suzhou Ribo Licenses siRNA Delivery System from Life Techologies

publication date: Jun 19, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Suzhou Ribo Life Sciences and Life Technologies of California have stuck a deal giving Ribo exclusive China rights to develop and manufacture siRNA therapeutics using Life's Invivofectamine® Rx delivery technology. Life Technologies will receive milestones and royalties for each drug that Ribo develops. Ribo’s first product is a treatment for hepatitis B. Invivofectamine® was originally produced as a research tool for knocking out genes in small-animal research models. Invivofectamine® Rx is based around a new class of lipid molecules that is 100-fold more powerful than the research product, while being less toxic, according to Life. More details....

Stock Symbol: (NSDQ: LIFE)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners